ÂÜÀòÂÒÂ×

Ben Strain joined Foghorn Therapeutics in 2021 as vice president of investor relations and corporate communications. He brings over 20 years of experience and most recently led the investor relations and communications functions for Paratek Pharmaceuticals and Biogen, where he successfully guided the investor communication strategy for a diverse set of preclinical and clinical candidates and nine new product launches in four distinct therapeutic areas including neurology, infectious disease, hematology and rare disease.

Prior to his roles at Paratek and Biogen, Ben was an instrumental member of the investor relations function at Under Armour and held positions of increasing responsibility at The Boston Company Asset Management, a subsidiary of the Bank of New York Mellon, making significant contributions to several U.S. and ex-US based equity funds.

Ben holds an MBA from McCallum Graduate School of Business at Bentley University and a BS in economics from Peter T. Paul College of Business and Economics at the University of New Hampshire.